Where does Edgewise Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$176.01M-20.5%	-$167.8M-25.4%	-$157.24M-26.5%	-$150.7M-30.1%	-$146.09M-38.0%
Depreciation and amortization	$2.06M-1.3%	$2.04M-0.6%	$2.09M+6.9%	$2.09M+12.6%	$2.09M+19.0%
Stock-based compensation	$34.41M+19.1%	$34.75M+40.6%	$32.61M+47.4%	$31.41M+58.6%	$28.9M+55.4%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	$1.05M+23.4%
Change in other assets	$3.44M+283%	$7.96M+342%	$3.66M+376%	$1.57M+153%	-$1.88M-158%
Change in operating lease liabilities	-$765K—	-$748K—	——	——	——
Net cash from operating activities	-$148.49M-25.5%	-$143.82M-31.9%	-$132.18M-21.4%	-$124.78M-20.5%	-$118.3M-21.1%
Capital expenditures	$472K-55.4%	$256K-80.5%	$457K-61.9%	$872K-23.2%	$1.06M-36.7%
Proceeds from maturities/sales of investments	——	——	——	——	——
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	$206.04M+1,881%	$196.09M-21.3%	$195.01M-34.9%	$196.68M-33.6%	$10.4M-96.5%
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$6.76M-40.3%	$7.67M-38.9%	$8.78M-27.5%	$9.97M-11.4%	$11.32M+6.9%
Depreciation	$2.06M-1.3%	$2.04M-0.6%	$2.09M+6.9%	$2.09M+12.6%	$2.09M+19.0%
Accrued compensation and employee benefits	——	——	——	——	$1.05M+23.4%
Operating lease liabilities	-$765K—	-$748K—	——	——	——
Accrued liabilities	$1.2M-12.9%	$691K-40.3%	$353K-21.6%	$792K—	$1.38M—
Increase (Decrease) in Prepaid Expense and Other Assets	$3.44M+283%	$7.96M+342%	$3.66M+376%	$1.57M+153%	-$1.88M-158%
Proceeds from maturities of investments	——	——	——	——	——
Payments Of Debt Issuance Costs	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	——
Finance Lease Right Of Use Asset Amortization	$194K-7.6%	$182K-17.6%	$184K-16.0%	$200K-2.0%	$210K+12.3%
Increase Decrease In Operating Lease Liability	-$765K—	-$748K—	——	——	——
Deferred Offering Costs Included In Accounts Payable And Accrued Other Expenses	——	——	——	——	——
Free cash flow	-$148.97M-24.8%	-$144.07M-30.6%	-$132.64M-20.5%	-$125.65M-20.0%	-$119.36M-20.1%
Free cash flow	-$148.97M-24.8%	-$144.07M-30.6%	-$132.64M-20.5%	-$125.65M-20.0%	-$119.36M-20.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Edgewise Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.